Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Open-label, Single-dose, Crossover Study to Evaluate the Bioequivalence of Four Formulations of Oral Rivoceranib Tablets in Healthy Subjects

Next Previous
Trial Profile

A Phase 1, Randomized, Open-label, Single-dose, Crossover Study to Evaluate the Bioequivalence of Four Formulations of Oral Rivoceranib Tablets in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Adenoid cystic carcinoma; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Osteosarcoma; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Uterine cancer
  • Focus Pharmacokinetics
  • Sponsors Elevar Therapeutics

Most Recent Events

  • 06 Jun 2023 Results assessing the bioequivalence of a single dose of rivoceranib administered as 4 different formulations in healthy subjects presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 01 Jun 2023 According to an Elevar Therapeutics media release, abstracts from this trial accepted for publication at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Jun 2-6 at McCormick Place in Chicago.
  • 15 Apr 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top